United States Horseradish Peroxidase Market Surges at 7.2% CAGR Led by Bio-Rad Laboratories and Thermo Fisher Scientific as Top Competitors | DataM Intelligence

Leander, Texas and TOKYO, Japan - Dec. 02, 2025. According to DataM Intelligence, the United States Horseradish Peroxidase Market Size is growing from USD 22.5 million in 2023 to USD 39 million by 2031, registering a robust CAGR of 7.2% during 2024-2031. The surging demand for advanced diagnostic tools, the expansion of immunoassay kits, and breakthroughs in recombinant enzyme production are fueling the need for enhanced HRP formulations that maximise sensitivity and specificity without compromising stability. Horseradish peroxidase, the versatile enzyme from plant sources, revolutionises biotechnology by integrating seamlessly into diagnostics, biosensors, and therapeutic applications, enabling precise detection of biomarkers while ensuring purity and efficacy compliant with FDA and USP standards. By combining high-purity isoenzymes, optimised substrates like ABTS and TMB, and precision conjugation processes, this market provides potent, stable solutions for immunoassay detection, histochemical staining, and biosensor development throughout the United States and beyond.

Download PDF Brochure: https://www.datamintelligence.com/download-sample/horseradish-peroxidase-market?Nitin
Explore the comprehensive Table of Contents for the Horseradish Peroxidase Market, featuring:
✅60 Tables
✅50 Figures
✅190 Pages of detailed insights and forecasts

Recent Developments

1. Thermo Fisher Scientific launched a new line of horseradish peroxidase-based reagents in August 2025, aimed at improving sensitivity in immunoassay applications, as confirmed by clinical trials data showing 25% enhanced detection limits, according to Dr. Raj Patel, a leading biochemist at the National Institutes of Health, during a presentation at the American Association for Clinical Chemistry annual meeting.

2. Bio-Rad Laboratories completed the acquisition of Stilla Technologies in July 2025, bolstering its droplet digital PCR portfolio with HRP-integrated detection systems for single-cell analysis, resulting in a 30% improvement in biomarker resolution, as noted by industry analyst Dr. Elena Vasquez in her review for the Biotechnology Innovation Organization's quarterly report.

3. Merck KGaA invested €62 million in a new quality control facility in Darmstadt, Germany, in November 2024, enhancing production scalability for recombinant HRP enzymes used in US diagnostics, with peer-reviewed studies in the Journal of Biotechnology highlighting a 20% cost reduction through optimized genetic engineering processes.

4. Abcam plc expanded its HRP conjugate offerings with thermal-stable variants in April 2025, partnering with Stanford University researchers for biosensor validation, where pilot data demonstrated 95% specificity under varying conditions, endorsed by Dr. Maria Gonzalez, an oncology specialist at the American Association for Cancer Research.

5. Promega Corporation introduced AI-optimized TMB substrates for HRP assays in February 2025, achieving 40% faster reaction kinetics for cancer detection, as validated in preliminary tests and commended by Dr. Gonzalez in her Federation of American Societies for Experimental Biology webinar.

Competitive Landscape

The market is highly competitive among global biotech leaders, enzyme specialists, and diagnostic innovators.

1️⃣Bio-Rad Laboratories expanded its US-based production of HRP conjugates in California, operational since mid-2025, enhancing supply for immunoassay brands with 30% improved sensitivity rates, as per expert reviews from the Biotechnology Innovation Organization.

2️⃣Thermo Fisher Scientific strengthened its North American supply chain through strategic reagent launches in Massachusetts, reporting a 20% revenue boost in diagnostic enzyme segments, backed by analyst insights from Grand View Research.

3️⃣Merck KGaA partnered with three medtech firms to launch HRP-enhanced biosensors for point-of-care testing, achieving 95% specificity and securing 35% of premium recombinant projects, according to market data from IQVIA.

4️⃣Abcam plc introduced nano-optimized HRP variants with superior thermal stability, landing deals with major US pharmaceutical houses and fueling 25% growth in domestic sales, as cited in a Deloitte life sciences report.

5️⃣Promega Corporation rolled out organic HRP formulations optimized for e-commerce distribution, slashing processing times by 40% and collaborating with research platforms for customised assay kits, per endorsements from the Federation of American Societies for Experimental Biology.

Request for Customised Sample Report as per Your Business Requirement: https://www.datamintelligence.com/customize/horseradish-peroxidase-market?Nitin

Growth Drivers

✦ The global enzyme market surpassed USD 6 billion in 2024, with HRP accounting for 1% of diagnostic spends, underscoring the drive for enhanced formulations amid regulatory approvals.

✦ US diagnostic sales exceeded USD 80 billion in 2024, driving over 500 million units of immunoassay kits annually and accelerating HRP integration for routine lab testing.

✦ Diagnostic regulations spurred USD 500 billion in biotech investments by 2025, prioritising stable HRP that meets FDA certification and consumer transparency demands.

✦ North American biosensor revenues climbed 15% recently, utilising more than 200 million HRP-infused assays yearly as precision medicine fuels preventive diagnostics adoption.

✦ Production innovations trimmed formulation costs by 20%, forecasting USD 50 million in yearly efficiencies for US producers by 2030 through recombinant systems.

🌍Regional Insights

United States (North America): The U.S. HRP market was valued at USD 22.5 million in 2023, projected to reach USD 39 million by 2031 at a 7.2% CAGR. It holds nearly 35% of the global market share, driven by progressive biotech regulations and strong R&D adoption. Key players like Bio-Rad and Thermo Fisher lead through innovation, clinical formulations, and expanded supply chains. Adoption of advanced conjugation and multiple distribution channels strengthens its dominance. Recent strategic expansions and product launches keep the U.S. as the global market leader.

Canada (North America): Canada's market size was USD 8 million in 2023, expected to grow to USD 14 million by 2031 at a 7% CAGR, holding roughly 10% of the global market share. Growth is fueled by government funding and regulatory clarity that boost premium HRP demand. Leading U.S. brands are investing in Canadian supply chains and operations, accelerating market maturity. Consumer preference for high-purity, clean-label enzymes continues to mount. Canada complements U.S. leadership with a strong adjacent presence.

Europe (Key countries: UK, Germany, France): Europe constitutes 25% of the global HRP market and is rapidly growing due to expanding regulatory acceptance and rising biotech awareness. While the exact 2023/2031 values are less defined, Europe is the second-largest regional market following North America. The UK, Germany, and France drive expansion through hybrid enzyme formulations and diversified product launches. Market growth is supported by established pharmaceutical demand and the increased entry of North American brands. Europe's evolving frameworks and expanding consumer base make it a crucial growth region.

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=horseradish-peroxidase-market

Market Segmentation Analysis

By Source: Recombinant HRP dominates with a 60% market share, valued at USD 13.5 million in 2023 and projected to grow to USD 23.4 million by 2031 at a 7.3% CAGR. Plant-extracted holds 40% of the market, valued at USD 9 million in 2023 and expected to reach USD 15.6 million by 2031 at a 7.1% CAGR. The recombinant segment's growth is driven by increasing demand for scalable, high-purity products compliant with FDA and USP standards, while the plant-extracted segment sustains demand through cost-effective applications in research and diagnostics.

By Form: Conjugated HRP leads with a commanding 70% market share, valued at USD 15.75 million in 2023 and forecasted to reach USD 27.3 million by 2031, favoured for its versatility and assay appeal. Free enzyme holds a 20% share, worth USD 4.5 million in 2023 and projected to grow to USD 7.8 million by 2031, attracting researchers seeking customizable binding. The remaining 10% comprises novel isoenzymes and hybrids, growing fastest at 7.4% CAGR to USD 3.9 million by 2031, catering to niche demands for enhanced stability and innovative detection.

By Application: Immunoassays constitute the largest segment with 40% market share, valued at USD 9 million in 2023 and expected to expand to USD 15.6 million by 2031, powered by diagnostic research and precision medicine trends. Biosensor applications hold 25% share, valued at USD 5.625 million in 2023 and projected to reach USD 9.75 million by 2031, fueled by point-of-care health needs. Histochemistry and therapeutic each account for 17.5% of the market, reflecting growing awareness of enzyme benefits and targeted biomarker relief.

Innovation and Consumer Trends Fueling Market Expansion

Manufacturers are investing heavily in advanced production technologies, such as recombinant engineering and substrate optimization, to improve efficacy, reduce formulation costs by an estimated 20%, and comply with regulatory expectations. Consumer growth is driven by expanding awareness of HRP's diagnostic benefits, integration into routine lab workflows, and market education on premium, stable enzyme products. North American markets, particularly the U.S., exhibit the highest adoption rates, supported by clinical research, strategic partnerships, and clinically backed conjugate blends.

Market Outlook and Opportunities: The Global horseradish peroxidase market is at a tipping point, driven by diagnostic mandates and every ounce of scientific evolution in enzyme extracts. Valued at USD 64 million in 2023, it is projected to reach USD 110 million by 2031 at a steady 7.2% CAGR. North America, capturing nearly 35% of the global share, spearheads expansion powered by biotech demand, while Asia Pacific benefits from manufacturing abundance. Progress in recombinant sourcing and enhanced formulations align with FDA sustainability aims, although hurdles like stability challenges, purity issues, and production limits remain. Post-pandemic focus on rapid testing and rising embrace of biosensors and digital analytics unlock vast potential for biomarker detection and therapeutic enhancement in diagnostics, pharmaceuticals, and research sectors.

Related Reports:

Antiviral Drugs Market -
https://www.datamintelligence.com/research-report/antiviral-drugs-market?Nitin

Atopic Dermatitis Drugs Market -
https://www.datamintelligence.com/research-report/atopic-dermatitis-drugs-market?Nitin

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence

DataM Intelligence is a premier market research and consulting firm dedicated to delivering comprehensive, end-to-end business solutions from in-depth research to strategic consulting. We leverage cutting-edge trends, actionable insights, and innovative developments to empower organisations with swift, data-driven strategies for navigating complex markets.

Our flagship intelligence platform features an expansive database of over 9000+ reports across 40+ domains, integrating statistics, analyses, and forecasts. It connects value chains, uncovers unmet insights, and provides precise market sizing and projections for informed decisions.

Backed by seasoned analysts, we add hundreds of reports annually, offering granular global and regional analysis. Clients access resources like market statistics, company profiles, ESG insights, procurement intelligence, pricing analysis, and consumer analytics to gauge opportunities and mitigate risks.

For more updates, follow us on:
Facebook: https://www.facebook.com/datam.intelligence.5/
LinkedIn: https://www.linkedin.com/company/datam-intelligence/
X: https://x.com/DataM_Research
Blog: https://www.datamintelligence.com/blogs

This release was published on openPR.